NKB2.F TG Therapeutics Inc

Healthcare Biotechnology Frankfurt Exchange
59.00 EUR
Close of Nov 13, 2026
23.22 59.00
Market cap
EUR 8.92B
P/E
101.7x
P/B
16.94x
ROE
19.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NKB2.F undervalued?

Graham number

The Graham number of TG Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

TG Therapeutics Inc fundamental analysis

No fundamental analysis for TG Therapeutics Inc yet.

TG Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disea…

Full company profile